Abstract: With the technological progress of percutaneous coronary intervention (PCI), suvival rate and the quality of life have been improved in patients with coronary heart disease, moreover, PCI has entered a new development stage with the wide application of drug eluting stents (DES) in the last decade. Nevertheless, in-stent restenosis disease is still tough to deal with. Drug-eluting balloon (DEB) can deliver the antiproliferative drug to the target lesions without stent implantation, so as to reduce the restenosis rate by inhibition of inflammation reaction and intima hyperplasy induced by implants. Therefore, DEB has special advantages in PCI of in-stent restenosis.